HR advanced cancer
Showing 1 - 25 of >10,000
Breast Cancer Trial in Wuhan (Adebrelimab, dalpiciclib)
Recruiting
- Breast Cancer
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 20, 2023
Ribociclib in Combination With Hormonal Therapy in HR+/HER2-
Not yet recruiting
- Breast Cancer
- ribociclib
- (no location specified)
Oct 10, 2023
HR+/HER2- Breast Cancer Trial (Tucidinostat, nab-paclitaxel)
Not yet recruiting
- HR+/HER2- Breast Cancer
- (no location specified)
Nov 21, 2022
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;
Recruiting
- Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
- dalpiciclib; fluvestrant; compound gossypol acetate tablets
-
Hangzhou, Zhejiang, ChinazhejiangCH
Nov 9, 2023
HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)
Recruiting
- HR+/HER2- Advanced Breast Cancer
- Targeted Therapy
- Everolimus
- +3 more
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Aug 1, 2023
Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide,fulvestrant)
Not yet recruiting
- Hormone Receptor-positive Advanced Breast Cancer
- (no location specified)
Apr 12, 2023
Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)
Recruiting
- Breast Cancer Metastatic Cancer
- Apatinib
- +2 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023
Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)
Recruiting
- Breast Cancer Metastatic Cancer
- Fluzoparib
- +2 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,
Not yet recruiting
- HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
- PERT-IJS plus trastuzumab, carboplatin and docetaxel
- Perjeta plus trastuzumab, carboplatin and docetaxel
- (no location specified)
Sep 21, 2023
Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast
Completed
- HR+/HER2- Advanced or Metastatic Breast Cancer
-
Dublin, IrelandNovartis Pharmaceuticals
May 2, 2023
Breast Cancer, Advanced Breast Cancer Trial in Shanghai (Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and
Not yet recruiting
- Breast Cancer
- Advanced Breast Cancer
- Everolimus 10 mg
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 14, 2023
Advanced HR+ HER2 Negative Breast Carcinoma Trial ((CDK)4/6 inhibitor)
Not yet recruiting
- Advanced HR+ HER2 Negative Breast Carcinoma
- (CDK)4/6 inhibitor
- (no location specified)
Sep 27, 2022
HR+/HER2- Advanced Breast Cancer Trial in Beijing (Dalpiciclib, Chidamide)
Not yet recruiting
- HR+/HER2- Advanced Breast Cancer
-
Beijing, Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
Oct 17, 2022
HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)
Recruiting
- HR Positive HER2 Negative Advanced Breast Cancer
-
Tianjin, China天津市肿瘤医院
May 26, 2023
Colorectal Cancer Trial (HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV,
Not yet recruiting
- Colorectal Cancer
- HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab
- HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
- (no location specified)
Jul 13, 2023
First-line Treatment of Advanced Pancreatic Cancer Trial (HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate,
Not yet recruiting
- First-line Treatment of Advanced Pancreatic Cancer
- HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
- nab-paclitaxel; gemcitabine
- (no location specified)
Feb 28, 2023
Among HR+/HER2- Advanced or Metastatic Breast Cancer in France
Recruiting
- Breast Cancer
- ribociclib + ET
-
La Roche sur Yon Cedex, FranceNovartis Investigative Site
Jan 16, 2023
Risarg® Combined With Endocrine Therapy or Chemotherapy in
Not yet recruiting
- HR+HER2- Advanced Breast Cancer
- Ribociclib
- Combination chemotherapy
- (no location specified)
Nov 20, 2023
Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)
Recruiting
- Breast Neoplasm
- +4 more
- PIK3CA inhibitor
- +12 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023
Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)
Not yet recruiting
- Hormone Receptor-positive Advanced Breast Cancer
- chidamide combined with fulvestrant
- (no location specified)
Mar 28, 2023
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)
Recruiting
- Metastatic Breast Cancer
- +2 more
-
Ocala, FloridaOcala Oncology Center PL DBA Florida Cancer Affiliates
Jul 19, 2023
